Thursday, September 17, 2026
MiningNewsTerminal
Thursday, September 17, 2026 Admin

LCR.CN ·

NeonMind Announces Management Change

Management Changes

NeonMind Announces Management Change

Oakville, Ontario – December 9, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink:NMDBF)

(FSE:6UF) (“NeonMind'' or the “Company”) announced today that Rob Tessarolo, a director on the

NeonMind Board of Directors, was appointed Chief Executive Officer and President on December 7,

2022. Mr. Tessarolo replaces Penny White, who has resigned as Chief Executive Officer and President as

of December 7, 2022 but continues to serve as a director of the Company.

Rob joined the Company in January 2021 and is an experienced executive who brings over 25 years of

experience in management. The CEO and Board of Directors are currently reviewing new opportunities

and are seeking a buyer for the Company’s drug development program.

About NeonMind Biosciences Inc.

NeonMind has been engaged in drug development of psychedelic compounds with two lead

psilocybin-based drug candidates targeting obesity. It is currently reviewing new opportunities.

Rob Tessarolo, Chairman of the Board, NeonMind Biosciences Inc.

[email protected]

Tel: 705-710-6366

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news

release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These

statements relate to future events or NeonMind's future performance. The use of any of the words

"could", "expect", "believe", "will", "projected","estimated" and similar expressions and statements

relating to matters that are not historical facts are intended to identify forward-looking information and

are based on NeonMind's current belief or assumptions as to the outcome and timing of such future

events. Actual future results may differ materially. In particular, NeonMind's drug development plans, its

ability to retain key personnel, and its expectation as to the development of its intellectual property and

other steps in its preclinical and clinical drug development constitute forward-looking information. Actual

results and developments may differ materially from those contemplated by forward-looking

information. Readers are cautioned not to place undue reliance on forward-looking information. Thestatements made in this press release are made as of the date hereof. NeonMind disclaims any intentionor obligation to publicly update or revise any forward-looking information, whether as a result of newinformation, future events or otherwise, except as may be expressly required by applicable securitieslaws.